Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Highlights from digestive disease week 2010.

Literature DB >> 21475386

Highlights from digestive disease week 2010.

Edward V Loftus¹.

Abstract

Year: 2010 PMID： 21475386 PMCID： PMC2950624

Source DB: PubMed Journal: Gastroenterol Hepatol (N Y) ISSN： 1554-7914

Keyword Cloud
References

× No keyword cloud information.

19 in total

Review 1. The genetics of inflammatory bowel disease.

Authors: Denise K Bonen; Judy H Cho
Journal: Gastroenterology Date: 2003-02 Impact factor: 22.682

2. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort.

Authors: N Gies; K I Kroeker; K Wong; R N Fedorak
Journal: Aliment Pharmacol Ther Date: 2010-05-25 Impact factor: 8.171

3. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

Authors: Jeffrey Hyams; Wallace Crandall; Subra Kugathasan; Anne Griffiths; Allan Olson; Jewel Johanns; Grace Liu; Suzanne Travers; Robert Heuschkel; James Markowitz; Stanley Cohen; Harland Winter; Gigi Veereman-Wauters; George Ferry; Robert Baldassano
Journal: Gastroenterology Date: 2006-12-03 Impact factor: 22.682

4. Management of Crohn's disease in adults.

Authors: Gary R Lichtenstein; Stephen B Hanauer; William J Sandborn
Journal: Am J Gastroenterol Date: 2009-01-06 Impact factor: 10.864

5. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.

Authors: William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Jean-Frédéric Colombel; Remo Panaccione; Geert D'Haens; Ju Li; Marie R Rosenfeld; Jeffrey D Kent; Paul F Pollack
Journal: Ann Intern Med Date: 2007-04-30 Impact factor: 25.391

6. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

Authors: Stephan R Targan; Brian G Feagan; Richard N Fedorak; Bret A Lashner; Remo Panaccione; Daniel H Present; Martina E Spehlmann; Paul J Rutgeerts; Zsolt Tulassay; Miroslava Volfova; Douglas C Wolf; Chito Hernandez; Jeffrey Bornstein; William J Sandborn
Journal: Gastroenterology Date: 2007-03-21 Impact factor: 22.682

Highlights from digestive disease week 2010.

Review 1. The genetics of inflammatory bowel disease.

2. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort.

3. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

4. Management of Crohn's disease in adults.

5. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.

6. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

7. Certolizumab pegol for the treatment of Crohn's disease.

8. Maintenance therapy with certolizumab pegol for Crohn's disease.

Review 9. Optimizing the use of tumour necrosis factor inhibitors in Crohn's disease: a practical approach.

10. Adalimumab for the treatment of fistulas in patients with Crohn's disease.